1. Neurological Disease

Neurological Disease

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W017443S4
    L-Asparagine-1,2,3,4-13C4 monohydrate 768348-44-3 98%
    L-Asparagine-1,2,3,4-13C4 monohydrate is the 13C labeled labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
    L-Asparagine-1,2,3,4-13C4 monohydrate
  • HY-W401531S1
    (R)-3-O-Methyldopa-d3 hydrochloride 2714485-35-3 98%
    (R)-3-O-Methyldopa-d3 (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine.
    (R)-3-O-Methyldopa-d3 hydrochloride
  • HY-10814
    CP-810123 439608-12-5 98%
    CP-810123 is a brain-permeable agonist of α7 nAChR for the research of cognitive impairment associated with psychiatric or neurological disorders such as schizophrenia and Alzheimer's disease.
    CP-810123
  • HY-10847
    SB-277011 215803-78-4 98%
    SB-277011 is a potent and delective dopamine D3 receptor antagonist (pKi values are 8.
    SB-277011
  • HY-11041
    LSP1-2111 936234-43-4 98%
    LSP1-2111 is a phosphinic glutamate derivative that agonists metabotropic glutamate (mGlu) receptor.
    LSP1-2111
  • HY-11054
    TH-237A 935467-97-3 98.55%
    TH-237A(meso-GS 164) is a neuroprotective agent with good blood-brain barrier permeability.
    TH-237A
  • HY-11071
    MK-0952 sodium 934995-88-7 98%
    MK-0952 sodium is a selective and orally active PDE4 inhibitor, with an IC50 of 0.53 nM. MK-0952 sodium has the potential for Alzheimer’s disease study.
    MK-0952 sodium
  • HY-12122
    AR-C102222 253771-21-0 98%
    AR-C102222 is a spirocyclic fluoropiperidine quinazoline selective iNOS inhibitor. AR-C102222 can be used for the research of neuropathic pain.
    AR-C102222
  • HY-12140
    Vestipitant 334476-46-9 98%
    Vestipitant (GW597599) is a neurokinin-1 receptor antagonist (pKi: 9.4, hNK1) with hypnotic effects and the ability to suppress primary insomnia. Vestipitant can effectively block substance P-mediated extracellular regulated kinase phosphorylation and relieve anxiety and possible depression induced by the agonist GR73632 (HY-P1192) in gerbils. Vestipitant can also improve functional dyspnea, anxiety, insomnia, irritable bowel disease, gastroesophageal reflux disease, tinnitus and antiemetic effects.
    Vestipitant
  • HY-12200
    GSK189254A hydrochloride 945493-87-8 98%
    GSK189254A hydrochloride is a novel, potent and selective histamine H3 receptor antagonist with pKi values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.
    GSK189254A hydrochloride
  • HY-12388
    N-Desmethyl clomipramine 303-48-0 98%
    Desmethylclomipramine (Norclomipramine) is a metabolite of Clomipramine (HY-B0457A) and can be used for neurological research.
    N-Desmethyl clomipramine
  • HY-12751
    Trimethobenzamide 138-56-7
    Trimethobenzamide (Ro 2-9578 free base) is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.
    Trimethobenzamide
  • HY-13225
    Rivanicline oxalate 220662-95-3 98%
    Rivanicline oxalate (RJR-2403 oxalate; (E)-Metanicotine oxalate) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM); > 1,000 fold selectivity than α7 receptors(Ki= 3.
    Rivanicline oxalate
  • HY-13769
    TPT-260 769856-81-7 98%
    TPT-260 (TPU260) is a temporary product name, and its molecular weight in the free base form is 260, which is a derivative of thiophene thioamide.
    TPT-260
  • HY-14128
    NBI-34041 268545-87-5 98%
    NBI-34041 (SB-723620) is a selective and orally active nonpeptide CRF1 receptor antagonist with an IC50 of 58.9 nM and a Ki of 4.0 nM for human CRF1 receptor. NBI-34041 has no inhibitory effect on the CRF2 receptor. NBI-34041 can be used for depression and anxiety disorders research.
    NBI-34041
  • HY-14205
    NW-1772 911290-35-2 98%
    NW-1772 (methanesulfonate) (compound 22b) is a potent and selective monoamine oxidase (MAO) B inhibitor. NW-1772 has some advantages, such as rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. NW-1772 can be used for the research of neurodegenerative diseases.
    NW-1772
  • HY-14338
    Idalopirdine 467459-31-0 98%
    Idalopirdine (Lu AE58054 ) is a potent, selective 5-HT6 receptor antagonist with a Ki value of 0.83 nM. Idalopirdine may be used in studies of Alzheimer's disease and schizophrenia, among other related disorders.
    Idalopirdine
  • HY-14353
    GSK-9772 928035-84-1 98%
    GSK-9772 is a Liver X Receptor (LXR) modulator of the N-phenyl tertiary amine class (NPTAs) with high affinity for LXR β ligand (IC50=30 nM). GSK-9772 has anti-inflammatory activity by binding to LXR, specifically by interacting with the region associated with the transcriptional repression function of the receptor, thereby inhibiting the expression of pro-inflammatory genes. GSK-9772 can be used in the study of inflammatory and neurodegenerative diseases.
    GSK-9772
  • HY-14409
    Lu AA41063 851202-49-8 98%
    Lu AA41063 is an adenosine A2A receptor antagonist that may be useful in the treatment of Parkinson's disease. Lu AA41063 has a Ki value of 5.9 nM and targets the human A2A receptor.
    Lu AA41063
  • HY-14477
    UPF-1035 370872-09-6 98%
    UPF-1035 is a selective PARP-2 inhibitor with an IC50 value of 0.15 μM. UPF-1035 increases CA1 pyramidal cell loss in hippocampal and has neuroprotective activity.
    UPF-1035
Cat. No. Product Name / Synonyms Application Reactivity